Cost-minimizing alternative dosage regimens of imipenem/cilastatin/relebactam for patients with renal impairment: a pharmacokinetic/pharmacodynamic simulation study
European Journal of Clinical Pharmacology · 2026
DOI: 10.1007/s00228-025-03944-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Xiaoping Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Renal Insufficiency, Cilastatin, Imipenem Drug Combination, Azabicyclo Compounds. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission Clinical Research Youth Project.
Abstract (Originalsprache)
PURPOSE: Renal function significantly influences the pharmacokinetics of imipenem/cilastatin/relebactam (IMI/REL). The standardized single-dose packaging commonly leads to considerable drug wastage when the medication is administered to patients with renal impairment. This investigation aimed to develop and assess alternative dosage regimens that optimize drug utilization and minimize waste. METHODS: Through Monte Carlo simulations, we evaluated alternative regimens involving extended dosage intervals and prolonged infusion times across patients with various levels of renal impairment. We assessed probabilities of target attainment (PTA) against established pharmacokinetic/pharmacodynamic (PK/PD) targets and minimum inhibitory concentration (MIC) breakpoints, and evaluated the risk of drug overexposure. Additionally, we compared the alternative dosage regimens with standard regimens in terms of dose wastage and cost savings. RESULTS: The findings suggest that administering full doses of IMI/REL every 8-12 h with prolonged infusion achieves satisfactory PTAs without significant overexposure risks. These alternative regimens are anticipated to reduce direct medical costs by $335.84 to $671.68 daily compared to standard dosages. CONCLUSION: Alternative dosing regimens for IMI/REL in patients with renal impairment can optimize drug utilization, minimize waste, and provide significant cost savings. However, further clinical studies are necessary to validate the effectiveness and safety of these regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China. xiaozhu@fudan.edu.cn.
- Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China. lv.qianzhou@zs-hospital.sh.cn.
Förderung
- Shanghai Municipal Health Commission Clinical Research Youth Project
Zitieren
APA
Shi, X., Lao, D., Xu, Q., Li, X., Liu, B., He, Q., Zhu, X., & Lv, Q. (2026). Cost-minimizing alternative dosage regimens of imipenem/cilastatin/relebactam for patients with renal impairment: a pharmacokinetic/pharmacodynamic simulation study. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03944-1
Vancouver
Shi X, Lao D, Xu Q, Li X, Liu B, He Q, et al. Cost-minimizing alternative dosage regimens of imipenem/cilastatin/relebactam for patients with renal impairment: a pharmacokinetic/pharmacodynamic simulation study. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-025-03944-1
BibTeX
@article{Shi2026,
author = {Shi, Xiaoping and Lao, Donghui and Xu, Qing and Li, Xiaoyu and Liu, Bijue and He, Qingfeng and Zhu, Xiao and Lv, Qianzhou},
title = {Cost-minimizing alternative dosage regimens of imipenem/cilastatin/relebactam for patients with renal impairment: a pharmacokinetic/pharmacodynamic simulation study},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1007/s00228-025-03944-1}
}
EUVIMED